Skip to main content

Advertisement

SpringerLink
Log in

Clinical aspects of lung involvement: Lessons from idiopathic pulmonary fibrosis and the scleroderma lung study

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Interstitial lung disease (ILD) occurs frequently among patients with systemic slcerosis (SSc) and accounts for significant morbidity and mortality. SSc-ILD resembles idiopathic pulmonary fibrosis (IPF) in many respects; each is characterized by a restrictive ventilatory defect that results from an active fibrosing process in the lung interstitium, and each is characterized by ground glass opacification on high resolution computed tomography (HRCT) and inflammatory cells in bronchoalveolar lavage fluid (BALF). Differences in the classification of lung histopathology are noted frequently and may account for some of the difference in outcome for patients with SSc-ILD and IPF. Optimal treatment of SSc-ILD remains to be determined, but cyclophosphamide has been reported to be effective in a number of case series. A randomized controlled trial, the Scleroderma Lung Study (SLS), will be completed in 2005; the outcome of the SLS should define the efficacy of daily oral cyclophosphamide for SSc-ILD patients with alveolitis defined by BALF and HRCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Steen VD, Medsger TA: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000, 43:1074–1084.

    Article  Google Scholar 

  2. Silver RM: Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am 1996, 22:825–840.

    Article  PubMed  CAS  Google Scholar 

  3. Morelli S, Barbieri C, Sgreccia A, et al.: Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997; 24:81–85.

    PubMed  CAS  Google Scholar 

  4. Diot E, Boissinot E, Asquier E,etal.: Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest 1998, 114:1623–1629.

    PubMed  CAS  Google Scholar 

  5. Wells AU, Rubens MB, du Bois RM, Hansell DM: Serial CT in fibrosing alveolitis. Am J Roentgen 1993, 161:1159–1165.

    CAS  Google Scholar 

  6. D’Angelo W, Fries J, Masi A, et al.: Pathologic observations in systemic sclerosis (scleroderma). Am J Med 1969, 46:428–440.

    Article  PubMed  CAS  Google Scholar 

  7. Weaver AL, Divertie MB, Titus JL: Pulmonary scleroderma. Chest 1968, 54:490–498.

    CAS  Google Scholar 

  8. Rossi GA, Bitterman PB, Ferrans VJ, Crystal RG: Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Resp Dis 1985, 131:612–617.

    PubMed  CAS  Google Scholar 

  9. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646–664.

    Google Scholar 

  10. Kim DS, Yoo B, Lee JS, et al.: The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:121–127.

    PubMed  Google Scholar 

  11. Bouros D, Wells AU, Nicholson AG, etal.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Resp Crit Care Med 2002, 165:1581–1586.This is the largest analysis of histopathologic subsets of SSc-ILD, indicating that the majority of patients (77.5%) have a pattern of NSIP and that such a pattern is associated with improved survival compared with SSc patients having a pattern of UIP or end-stage lung fibrosis. Outcome is linked more strongly to disease severity at presentation and serial DLCO trends than to histopathologic findings.

    Article  PubMed  Google Scholar 

  12. Fujita J, Yoshinouchi T, Ohtsuki Y, et al.: Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001, 60:281–283.

    Article  PubMed  CAS  Google Scholar 

  13. Flaherty KR, Travis WD, Colby TV, et al.: Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Resp Crit Care Med 2001, 164:1722–1727.

    PubMed  CAS  Google Scholar 

  14. Guttadauria M, Ellman H, Emmanuel G, et al.: Pulmonary function in scleroderma. Arthritis Rheum 1977, 20:1071–1079.

    Article  PubMed  CAS  Google Scholar 

  15. Remy-Jardin M, Remy J, Wallaert B, et al.: Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests and bronchoalveolar lavage. Radiology 1993, 188:499–506.

    PubMed  CAS  Google Scholar 

  16. Spagnolatti L, Zoia MC, Volpini E, et al.: Pulmonary function in patients with systemic sclerosis. Monaldi Arch Chest Dis 1997, 52:4–8.

    PubMed  CAS  Google Scholar 

  17. Jacobsen S, Halberg P, Ullman S, et al.: A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol 1997, 16:384–390.

    Article  PubMed  CAS  Google Scholar 

  18. Steen VD, Grahm G, Conte C, et al.: Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992, 35:765–770.

    Article  PubMed  CAS  Google Scholar 

  19. Steen VD, Medsger TA Jr.: Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516–522.

    Article  PubMed  Google Scholar 

  20. Terriff BA, Kwan SY, Yeng MC, Muller NL: Fibrosing alveolitis: chest radiography and CT as predictors of clinical and functional impairment at follow-up in 26 patients. Radiology 1992, 184:445–449.

    PubMed  CAS  Google Scholar 

  21. Warrick JH, Bhalla M, Schabel SI, Silver RM: High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991, 18:1520–1528.

    PubMed  CAS  Google Scholar 

  22. Ooi GC, Mok MY, Tsang KW, et al.: Interstitial lung disease in systemic sclerosis. Acta Radiol 2003, 44:258–264.

    Article  PubMed  CAS  Google Scholar 

  23. MacDonald SL, Rubens MB, Hansell DM, et al.: Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances and diagnostic accuracy of thinsection CT. Radiol 2001, 221:600–605.

    Article  CAS  Google Scholar 

  24. Lee JS, Im JG, Ahn JM, et al.: Fibrosing alveolitis: prognostic implication of ground-glass attenuation at high-resolution CT. Radiology 1992, 184:451–454.

    PubMed  CAS  Google Scholar 

  25. Desai SR, Veeraraghavan S, Hansell DM, et al.: CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004 232:560–567.

    Article  PubMed  Google Scholar 

  26. White B, Moore WC, Wigley FM, et al.: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947–954.

    PubMed  CAS  Google Scholar 

  27. Clements PJ, Goldin JG, Kleerup EC et al.: Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004, 50:1909–1917.

    Article  PubMed  Google Scholar 

  28. Cailes JB, O’Connor C, Pantelidis P, et al.: Neutrophil activation in fibrosing alveolitis: a comparison of lone cryptogenic fibrosing alveolitis and systemic sclerosis. Eur Resp J 1996, 9:992–999.

    Article  CAS  Google Scholar 

  29. Silver RM, Miller KS, Kinsella MB, et al.: Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990, 88:470–476.

    Article  PubMed  CAS  Google Scholar 

  30. Behr J, Vogelmeier C, Beinert T, et al.: Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Resp Crit Care Med 1996, 154:400–406.

    PubMed  CAS  Google Scholar 

  31. Witt C, Borges AC, John M, et al.: Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999, 58:635–640.

    Article  PubMed  CAS  Google Scholar 

  32. Wells AU, Cullinan P, Hansell DM, et al.: Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Resp Crit Care Med 1994, 149:1583–1590.

    PubMed  CAS  Google Scholar 

  33. Veeraraghavan S, Latsi PI, Wells AUA, et al.: BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Resp J 2003, 22:239–244.

    Article  CAS  Google Scholar 

  34. Bolster MB, Ludwicka A, Sutherland S, et al.: Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997, 40:743–751.

    Article  PubMed  CAS  Google Scholar 

  35. Meloni F, Caporali R, Marone Bianco A, et al.: Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: comparison with usual interstitial pneumonia. Ann Rheumatol Dis 2004, 63:892–894.

    Article  CAS  Google Scholar 

  36. Rizou C, Ioannidis JP, Panou-Pomonis E, et al.: B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis. Am J Respir Cell Mol Biol 2000, 22:344–351.

    PubMed  CAS  Google Scholar 

  37. Diot E, Giraudeau B, Diot P, et al.: Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999, 116:715–720.

    Article  PubMed  CAS  Google Scholar 

  38. Bredemeier M, Xavier RM, Capobianco KG, et al.: Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol 2004, 31:286–294.

    PubMed  Google Scholar 

  39. Silver RM, Metcalf JF, Stanley JH, LeRoy EC: Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum 1984, 27:1254–1262.

    Article  PubMed  CAS  Google Scholar 

  40. Fajac I, Kahan A, Menkes CJ, et al.: Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exper Rheum 1998, 16:547–552.

    CAS  Google Scholar 

  41. Kharitonov S, Alving K, Barnes PJ: ERS task report: exhaled and nasal nitric oxide measurement; recommendations. Eur RespJ 1997, 10:1683–1693.

    Article  CAS  Google Scholar 

  42. Moodley YP, Lalloo UG: Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease. Chest 2001, 119:1449–1454.

    Article  PubMed  CAS  Google Scholar 

  43. Sato S, NagaokaT, Hasegawa M, et al.: Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatolol 2000, 200:196–201.

    Article  CAS  Google Scholar 

  44. Vesely R, Vargova V, Ravelli A, et al.: Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. J Rheumatol 2004, 31:795–800.

    PubMed  Google Scholar 

  45. Yanaba K, Hasegawa M, Hamaguchi Y, et al.: Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exper Rheum 2003, 21:429–436.

    CAS  Google Scholar 

  46. Phelp DS, Umstead TM, Mejia M, et al.: Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest 2004, 125:617–625.

    Article  Google Scholar 

  47. Takahashi H, Kuroki Y, Tanaka H, et al.: Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Resp Crit Care Med 2000, 12:258–263.

    Google Scholar 

  48. Asano Y, Ihn H, Yamane K, et al.: Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001, 44:1363–1369.

    Article  PubMed  CAS  Google Scholar 

  49. Yanaba K, Hasegawa M, Takehara K, Sato S: Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rhematol 2004, 31:1112–1120.Serum levels of surfactant protein-D(SP-D) and KL-6 were measured in 42 Japanese SSc patients, including a retrospective longitudinal study of 83 samples from 6 patients. SP-D was a more sensitive marker for ILD than KL-6, and KL-6 showed higher specificity than SP-D. SP-D levels were more responsive to change and tended to reflect ILD activity more so than KL-6.

    CAS  Google Scholar 

  50. Akesson A, Scheja A, Lundin A, Wollheim FA: Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994, 37:729–735.

    Article  PubMed  CAS  Google Scholar 

  51. Silver RM, Warrick JH, Kinsella MB, et al.: Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993, 20:834–844.

    Google Scholar 

  52. Steen VD, Lanz JK Jr, Conte C, et al.: Therapy for severe interstitial lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1290–1296.

    Article  PubMed  CAS  Google Scholar 

  53. Pakas I, Ioannidis JP, Malagari K, et al.: Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002, 29:298–304.

    PubMed  CAS  Google Scholar 

  54. Griffiths B, Miles, S, Moss H, et al.: Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect of high resolution computed tomography scan and lung function. J Rheumatol 2002, 29:2371–2378.

    PubMed  CAS  Google Scholar 

  55. Airo P, Danieli E, Parinello, et al.: Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exper Rheum 2004, 22:573–578.

    CAS  Google Scholar 

  56. Apras S, Ertenli I, Ozbalkan Z, et al.: Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003, 48:2256–2261.

    Article  PubMed  CAS  Google Scholar 

  57. Davas EM, Peppas C, Maragou M, et al.: Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999, 18:455–461.

    Article  PubMed  CAS  Google Scholar 

  58. Collard HR, Ryu JH, Douglas WW, etal.: Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004, 125:2169–2174.

    Article  PubMed  CAS  Google Scholar 

  59. Furst DE, Clements PJ, Tashkin D, Elashoff R: Among a group of patients with dyspnea and alveolitis entering the scleroderma lung study (SLS), a surprising proportion have limited SSc (LSSc). Arthritis Rheum 2005, 52:In press. This is one of the first papers to emanate from the SLS. The authors report the demographic, clinical and spirometric features of the study population, all of whom fulfilled the entry criterion of alveolitis defined by BAL and/or HRCT. Of note, 40% of the SLS patients had lcSSc.

  60. Tashkin DP, Clements P, Goldin J, et al.:The scleroderma lung study (SLS): baseline features and dyspnea-lung function correlations. Am J Respir Crit Care Med 2004, 169:A225.

    Google Scholar 

  61. Khanna D, Clements PJ, Furst DE, et al.: Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the scleroderma lung study. Arthritis Rheum 2005, 52:592–600.SSc-ILD patients with greater severity of dyspnea have lower health-related quality of life, greater functional disability, poorer patient global assessment of their disease and greater decreases in physiologic measures of lung function (FVC and DLCO). In this report from the SLS the patient self-assessed measures of disease was noted to be a stronger correlate of dyspnea than were physiologic measures.

    Article  PubMed  Google Scholar 

  62. Silver R, Goldin JG, Strange C, et al.: Alveolitis determination in scleroderma lung disease: CT or bronchoalveolar lavage (BAL)? Am J Respir Crit Care Med 2004, 169:A227.

    Google Scholar 

  63. Tobin RW, Pope CE 2nd, Pellegrini CA, et al.: Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158:1804–1808.

    PubMed  CAS  Google Scholar 

  64. Marie I, Dominique S, Levesque H, et al.: Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001, 45:346–354.

    Article  PubMed  CAS  Google Scholar 

  65. Ing AJ: Interstitial lung disease and gastroesophageal reflux. Am J Med 2001, 111:41S-44S.

    Article  PubMed  Google Scholar 

  66. Chang B, Wigley FM, White B, Wise RA: Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003, 30:2398–2405.In this retrospective cross-sectional study of over 600 SSc patients, 18% was noted to have both ILD and PH. Patients with this combination resembled SSc patients with ILD by being more likely to have diffuse cutaneous SSc and antitopoisomerase antibodies, but they tended to be older at diagnosis and at disease onset and to have a higher mortality risk ratio.

    PubMed  Google Scholar 

  67. Strange C, Bolster M, Mazur J, et al.: Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000, 118:1077–1082.

    Article  PubMed  CAS  Google Scholar 

  68. Nicholson AG, Colby TV, du Bois RM, et al.: The prognostic significance of the histological pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000, 162:2213–2217.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912 CSB, 29425, Charleston, SC, USA

    Richard M. Silver MD

Authors
  1. Kristin B. Highland MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard M. Silver MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Highland, K.B., Silver, R.M. Clinical aspects of lung involvement: Lessons from idiopathic pulmonary fibrosis and the scleroderma lung study. Curr Rheumatol Rep 7, 135–141 (2005). https://doi.org/10.1007/s11926-005-0066-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-005-0066-z

Keywords

Search

Navigation